Skip to content
Open access

Adipose-derived microRNA-518a drives hepatic cholesterol dysregulation and hypertension-related vascular remodeling in metabolic dysfunction-associated steatohepatitis via the MST1-AMPK-SREBP2 axis.

Sep 2026 · Clinical and experimental hypertension · Vol 48 1, pp. 2716134 · 0 citations · 69 references
Medicine

TL;DR

MicroRNA-518a promotes hepatic cholesterol dysregulation and MASH progression by targeting the MST1-AMPK-SREBP2 signaling pathway, and the convergence of this axis with vascular regulatory networks suggests broader implications for understanding the metabolic-vascular comorbidities frequently observed in MASH patients, including hypertension and arterial stiffness.

Abstract

INTRODUCTION Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by disrupted hepatic lipid homeostasis and progressive liver injury, and frequently coexists with hypertension and systemic vascular remodeling, suggesting shared pathophysiological mechanisms. Although adipose tissue-derived microRNAs have emerged as important mediators of inter-organ communication, their roles in regulating hepatic cholesterol metabolism and vascular dysfunction during MASH remain incompletely understood.

Objectives

This study aimed to investigate whether microRNA-518a regulates hepatic cholesterol metabolism and MASH progression through the MST1-AMPK-SREBP2 signaling pathway and to explore its potential implications for vascular remodeling and hypertension.

Methods

Integrative bioinformatic analyses, including Mendelian randomization and transcriptomic network analysis, were performed to identify candidate regulatory pathways associated with MASH. Functional validation was conducted using human clinical samples, in vitro cell models, exosome-mediated microRNA delivery, and a dietary mouse model of MASH.

Results

MST1 was identified as a key regulatory target of microRNA-518a. Increased microRNA-518a expression suppressed MST1, resulting in reduced AMPK activation and enhanced SREBP2-mediated cholesterol biosynthesis. Functional experiments demonstrated that microRNA-518a promoted hepatic cholesterol accumulation, lipid deposition, inflammation, and fibrotic changes, whereas restoration of MST1 partially reversed these effects. Exosome-mediated delivery of microRNA-518a further supported its ability to modulate hepatic metabolic responses through intercellular communication.

Conclusions

MicroRNA-518a promotes hepatic cholesterol dysregulation and MASH progression by targeting the MST1-AMPK-SREBP2 signaling pathway. Notably, the convergence of this axis with vascular regulatory networks suggests broader implications for understanding the metabolic-vascular comorbidities frequently observed in MASH patients, including hypertension and arterial stiffness.

Read PDF

Similar papers

Open access Oct 2026

TAK1 Is Associated with Lipid-Induced Macrophage Polarization in Obesity Cardiomyopathy: Evidence from Network Pharmacology and Experimental Validation

Objective: To investigate whether TAK1 regulates lipid-induced macrophage polarization and contributes to inflammatory progression in obesity cardiomyopathy (OCM). Background: OCM is characterized by lipid overload, chronic low-grade inflammation, macrophage polarization imbalance, and myocardial remodeling. Preliminar...

Cong-Xiang Yi, Ye Pu, Di Chen et al. · 0 citations
Review Open access Oct 2026

MicroRNAs in Alcohol-Associated Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenic Networks and Disease Progression to Precision Biomarkers and Therapeutic Strategies

The involvement of miRNAs throughout the progression of ALD and MASLD is comparatively examined, with particular emphasis on their roles in lipid metabolic dysregulation, mitochondrial and oxidative stress, autophagic dysfunction, immune activation, hepatocyte death, and hepatic-stellate-cell-associated fibrogenesis.

Minkyoung Gu, Chaebin Park, S. Kim et al. · 0 citations
Sep 2026

Sinusoidal endothelial cells orchestrate liver inflammation and lipid metabolism via USP12/CD36 axis being the target of celastrol therapy.

Disordered lipid metabolism and inflammation, the hallmark features of metabolic dysfunction-associated steatohepatitis (MASH), present a significant therapeutic challenge even in the absence of obesity, making the discovery of novel pathogenic mechanisms and therapies imperative. Although Celastrol (Cel) markedly amel...

Hu Hua, Wen-Ping Zhu, Le-Hang Sun et al. · 0 citations
Oct 2026

An MMP12-Enriched Kupffer Cell-Associated Programme Links ATF3-Associated Immunometabolic Remodeling to Hepatic Metabolic Dysfunction and Fibrotic Communication Networks.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cause of chronic liver injury, yet the cellular programmes linking metabolic stress with inflammation and fibrosis remain incompletely understood. Here, we integrated single-cell transcriptomics, regulatory network analysis, functional validati...

Jing He, Wang Zhang, Pan-Pan Liu et al. · 0 citations
Oct 2026

Molecular mechanism of the LncRNA MALAT1/NF-κB signaling pathway in mediating vascular endothelial injury under glucose and lipid metabolism disorders.

BACKGROUND Disordered glucose and lipid metabolism exacerbates endothelial injury, promoting atherosclerosis (AS). This study aimed to elucidate the role of the lncRNA MALAT1 in endothelial injury under high glucose and palmitic acid (HGPA) conditions via in vivo and in vitro experiments. METHODS Bioinformatics ident...

G. Aihemaiti, Fen Liu, N. Song et al. · 0 citations
Open access Sep 2026

Yinqi Tiaozhi Decoction ameliorates hepatic steatosis in metabolic dysfunction-associated fatty liver disease by regulating the miR-122-5p/FOXO3 axis to modulate lipid metabolism and oxidative stress

YQTZD mitigates hepatic steatosis, oxidative damage, and inflammation in MAFLD, mechanistically linked to miR-122-5p downregulation-mediated FOXO3 upregulation and provides a mechanistic foundation for its future integration into clinical management of MAFLD.

Li-Ping Zhou, Yan-Feng Huang, F. Tian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.